Protect the Head to Head Study (ProtectH2H)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05684146 |
Recruitment Status :
Recruiting
First Posted : January 13, 2023
Last Update Posted : May 19, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Embolism | Device: Emboliner Embolic Protection Device: Sentinel Cerebral Protection | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 540 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | G4: Model Description* Subjects will be randomized (1:1) to either the Emboliner (ARM 1) or Sentinel CPS (ARM 2). Device randomization will be stratified by (a) site and (b) TAVR device type (Edwards or Medtronic) to ensure that each study arm represents an equivalent patient population. |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Protect the Head to Head: A Safety and Efficacy Assessment of the Emboliner Embolic Protection Device |
Actual Study Start Date : | May 4, 2023 |
Estimated Primary Completion Date : | October 2024 |
Estimated Study Completion Date : | December 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: Emboliner Embolic Protection Device
Emboliner embolic protection device to be used during TAVR procedures for stroke prevention
|
Device: Emboliner Embolic Protection
Emboliner Embolic Protection Device will be used to capture and remove embolic material during transcatheter aortic valve replacement (TAVR) interventions
Other Name: Embolic protection |
Active Comparator: Sentinel Cerebral Protection System
Sentinel Cerebral Protection System to be used during TAVR procedures for stroke prevention
|
Device: Sentinel Cerebral Protection
The Sentinel Cerebral Protection System will be used to capture and remove embolic material during transcatheter aortic valve replacement (TAVR) interventions
Other Name: Embolic protection |
- Non-inferiority [ Time Frame: Non-inferiority of 30-day Emboliner device MACCE patient incidence rate compared to the Sentinel device patient incidence rate. ]
Non-inferiority of 30-day Emboliner device MACCE patient incidence rate compared to the Sentinel device patient incidence rate.
K4: Description Non-inferiority of 30-day Emboliner device MACCE patient incidence rate compared to the Sentinel device patient incidence rate.
30 Days
- Non-inferiority VARC-2 [ Time Frame: 30 Days ]Non-inferiority of 30-day Emboliner device VARC 2-defined stroke incidence rate compared to the Sentinel device incidence rate.
- Debris Capture [ Time Frame: 30 Days ]The count (by number of particles >150 microns) of debris capture using the Emboliner device will be compared to the count of debris captured by the Sentinel device.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Eligible for treatment for symptomatic severe aortic stenosis using a FDA-approved TAVR valve according to current guidelines
- Consented to the TAVR procedure
- Subject and physician agree that subject will return for required post-procedure follow-up
- Willing to participate in study and provide signed EC/IRB-approved informed consent
- Eighteen (18) years or older at the time of consent
Exclusion Criteria:
- Not undergoing a planned TAVR via transfemoral access
- Severe allergy or hypersensitivity to aspirin, heparin or bivalirudin, clopidogrel or ticlopidine, nitinol, and/or contrast agents that cannot be pre-medicated
- Uncorrected bleeding disorder
- Hypercoagulation status that cannot be corrected by additional peri-procedural heparin
- Myocardial infarction (MI) diagnosis <30 days prior to study procedure
- History of substance abuse that may cause non-compliance with the protocol or confound the data interpretation
- Cardiogenic shock, hemodynamic instability requiring inotropic support or mechanical heart assistance, or severe hypotension (systolic blood pressure <90 mmHg) at time of screening
- History of a stroke < 180 days prior to study procedure
- Active peptic ulcer or history of upper gastrointestinal (GI) bleeding < 90 days prior to study procedure
- Congenital unicuspid aortic valve
- Porcelain aorta, asymmetrical or sharp aortic calcifications, severe aortic tortuosity, shaggy aorta or mobile atheroma in the arch
- Pre-existing prosthetic heart valve in any position, prosthetic ring, or severe (greater than 3+) mitral insufficiency
- Current leukopenia, acute anemia, thrombocytopenia, history of chronic bleeding diathesis, or coagulopathy that requires treatment
- Hypertrophic cardiomyopathy with or without obstruction
- Left ventricular ejection fraction (LVEF) ≤20%
- Echocardiographic evidence of intracardiac or aortic mass, thrombus, or vegetation
- Active infection or endocarditis
- Neurodegenerative or other progressive neurological disease or history of significant head trauma followed by persistent neurologic defaults
- Carotid stent placement or endarterectomy performed <180 days prior to study procedure.
- Severe renal insufficiency (creatinine >3.0 mg/dL or GFR <30 mL/min) or patient on dialysis
- Planned treatment with another investigational device or procedure during the study period
- Balloon valvuloplasty (BAV) within 30 days of the procedure
- Any planned surgical or interventional cardiac procedure (e.g., concurrent coronary revascularization or AF ablation) during the TAVR procedure, within 30 days before or after the TAVR procedure
- Emergency surgery for any reason
- Pregnancy, lactation or intent to become pregnant during study participation
- Unable or unwilling to complete all required screening and/or follow-up assessments, including subjects with active major psychiatric disease; with severe visual, auditory, or learning impairment
- Investigator considers participation in the study not to be in the subject's best interest
- Dementia or any other cognitive deficit that results in inability to provide informed consent or comply with the study protocol
- Presence of hemodialysis shunt, graft, or arterio-venous fistula involving access vasculature
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05684146
Contact: Laura A Brenton | +1 313 919 8044 | lbrenton@emboline.com | |
Contact: Duda Markovic | +1 858 220 2777 | dmarkovic@emboline.com |
United States, New York | |
NewYork-Presbyterian/Columbia University Medical Center | Recruiting |
New York, New York, United States, 10032 | |
United States, Oklahoma | |
Oklahoma Heart Institute | Recruiting |
Tulsa, Oklahoma, United States, 74104 |
Study Director: | Laura A Brenton | Emboline, Inc. |
Responsible Party: | Emboline |
ClinicalTrials.gov Identifier: | NCT05684146 |
Other Study ID Numbers: |
TP-0527 |
First Posted: | January 13, 2023 Key Record Dates |
Last Update Posted: | May 19, 2023 |
Last Verified: | January 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Device Product Not Approved or Cleared by U.S. FDA: | Yes |
Product Manufactured in and Exported from the U.S.: | Yes |
MACCE TAVR Embolism |
Embolism Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases |